• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by DarioHealth Corp.

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email
    SC 13G 1 tm2431073d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

      

    DarioHealth Corp.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    23725P209

    (CUSIP Number)

     

    November 4, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    NAMES OF REPORTING PERSON

     

    Tasso Partners, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x(1)

    (b) ¨

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,016,043(2)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,016,043(2)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,016,043(2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    7.90% (3)

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)Tasso Partners, LLC owns the DarioHealth Corp. (the “Issuer”) shares; Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera controls Tasso Capital, LLC.

     

    (2)Consists of (i) 1,394,721 shares of common stock held by the Reporting Person, (ii) shares of Preferred C Stock convertible into 1,222,772 shares of common stock, and (iii) shares of Preferred C-2 Stock convertible into 23,364 shares of common stock, which are beneficially owned by Dana Carrera is the trustee of the Trust, and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.

     

    (3)The percentage ownership was calculated based on a denominator which is the sum of 38,185,640 Common Stock outstanding as of the filing date of this report.

      

     

     

     

    1.

    NAMES OF REPORTING PERSON

     

    Dana Carrera

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x(1)

    (b) ¨

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,016,043(2)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,016,043(2)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,401,043(3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    8.82% (4)

    12.

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)

     

    Tasso Partners, LLC owns the DarioHealth Corp. (the “Issuer”) shares; Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera controls Tasso Capital, LLC.
    (2) Consists of (i) 1,394,721 shares of Common Stock held by the Reporting Person, (ii) shares of Preferred C Stock convertible into 1,222,772 shares of common stock, and (iii) shares of Preferred C-2 Stock convertible into 23,364 shares of common stock, which are beneficially owned by Dana Carrera is the trustee of the Trust, and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.
       
    (3) Consists of (i) 1,394,721 shares of Common Stock held by the Reporting Person, (iii) shares of Preferred C Stock convertible into 1,222,772 shares of common stock, (iii) shares of Preferred C-2 Stock convertible into 23,364 shares of common stock, and (iv) warrants to purchase 385,000 shares of common stock owned by GCL Family Trust (the “Trust”), which are beneficially owned by Dana Carrera, the trustee of the Trust, and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.

     

    (4) The percentage ownership was calculated based on a denominator which is the sum of (i) 38,185,640 shares  of common stock outstanding as of the filing date of this report, (ii) shares of Preferred C Stock convertible into 1,222,772, (iii) shares of Preferred C-2 Stock convertible into 23,364 shares of common stock, and (iv) warrants to purchase 385,000 shares of common stock, which are beneficially owned by Dana Carrera and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended.

     

     

     

     

    Item 1.   Issuer
         
      (a) Name of Issuer:
         
        DarioHealth Corp.
         
      (b) Address of Issuer’s Principal Executive Offices:
         
        322 W 57TH ST. #33B NEW YORK, NY, 10019
         
    Item 2.   Filing Person
         
      (a) – (c) Name of Persons Filing; Address; Citizenship:
       

     

    This statement is filed on behalf of:

    (1)    Tasso Partners, LLC

    (2)    Dana Carrera

     

    The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which such Reporting Persons have agreed to file this Schedule 13G and all subsequent amendments to the Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    The filing of this Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock reported herein.

     

    The principal business address of each of the Reporting Persons is:

     

    P.O. Box 503

    Rumson, NJ 07760

     

    Citizenship: Tasso Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dana Carrera is a citizen of the United States.

         
      (d) Title of Class of Securities:
         
        Common Stock, par value $0.0001 per share
         
      (e) CUSIP Number:
         
        23725P209

     

    Item 3.   If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

     

     

      

    Item 4.   Ownership

     

    Tasso Partners, LLC

     

      (a) Amount beneficially owned: 3,016,043 shares of common stock

     

      (b) Precent of class: 7.90%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 3,016,043

     

      (iii) Sole power to dispose or to direct the disposition of: 0

     

      (iv) Shared power to dispose or to direct the disposition of: 3,016,043

     

    Dana Carrera

     

      (a) Amount beneficially owned: 3,401,043 shares of common stock

     

      (b) Precent of class: 8.82%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 3,401,043

     

      (iii) Sole power to dispose or to direct the disposition of: 0

     

      (iv) Shared power to dispose or to direct the disposition of: 3,401,043

     

      Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

      Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

      Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

     

     

     

    Item 8.  

    Identification and Classification of Members of the Group.

     

    Tasso Partners, LLC owns the Issuer shares; Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera is the trustee of the Trust and controls Tasso Capital, LLC.

       
    Item 9.  

    Notice of Dissolution of Group.

     

    Not applicable.

       
    Item 10.  

    Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: December 13, 2024

     

    Tasso Partners, LLC  
         
    By: /s/ Dana Carrera  
    Name:  Dana Carrera  
    Title: Manager of Tasso Capital, LLC, which controls Tasso Partners, LLC  

      

     

    Dana Carrera  
         
    By: /s/ Dana Carrera  
    Name:  Dana Carrera  

     

     

     

     

     

     

    Get the next $DRIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      12/13/24 4:05:12 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DarioHealth Corp.

      SC 13G - DarioHealth Corp. (0001533998) (Subject)

      10/29/24 11:45:28 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

      SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

      2/14/24 4:51:40 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    See more
    • DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

      Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

      2/27/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

      Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

      10/28/24 4:44:00 PM ET
      $BMY
      $DRIO
      $NVS
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

      After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

      6/5/24 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Financials

    Live finance-specific insights

    See more
    • DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

      Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

      5/7/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results

      Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023.Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.Completed $25.6 million equity financing, resulting in a $34.5 million proforma cash balance as of year-end; proforma balance expected to fund operations through operational cash flow breakeven run rate by the end of 2025 with a larger cushion.Revenue growth and efficient post-merger integration resulted in a decrease in operating loss in the quarter ended December 31, 2024, of 35% to $11.7 million on a GAAP bas

      3/10/25 6:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth to Report Fourth Quarter and Full Year 2024 Results on Monday, March 10, 2025

      Company to host conference call and webcast at 8:30am Eastern Time NEW YORK, March 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Monday, March 10th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Monday, March 10th, 2025, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: ht

      3/4/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      11/14/24 4:15:15 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/12/24 4:37:42 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/10/24 6:00:13 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025

      Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 7, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Wednesday, May 14th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call DetailsDate: Wednesday, May 14th, 2025, 8:30 a.m. Eastern TimeDial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

      5/7/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives

      $32.5 million funded at close; up to $17.5 million of additional capital available at the Company's option, subject to the achievement of certain revenue thresholds.Capital from the transaction is expected to support execution of strategic plan and fuel continued growth.With this new structure, debt amortization is deferred from the end of 2025 to 2028, allowing the time to generate funds from operations to support the Company's cash flow.NEW YORK, May 1, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced the closing of a debt financing facility for up to $50 million provided by Rand Capital and Callodine

      5/1/25 8:30:00 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Announces CFO Transition

      NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity. "It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished,

      4/21/25 8:30:00 AM ET
      $BNRG
      $DRIO
      $PLUR
      Building Products
      Industrials
      Medical/Dental Instruments
      Health Care

    $DRIO
    SEC Filings

    See more

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • DarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - DarioHealth Corp. (0001533998) (Filer)

      5/6/25 7:30:24 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - DarioHealth Corp. (0001533998) (Filer)

      4/28/25 4:05:25 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - DarioHealth Corp. (0001533998) (Filer)

      4/21/25 5:10:40 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth downgraded by TD Cowen with a new price target

      TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

      1/29/25 7:36:04 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • DarioHealth upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

      5/13/22 9:01:42 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Aegis Capital reiterated coverage on DarioHealth with a new price target

      Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

      1/26/22 10:35:44 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • New insider Leisure Lawrence B. claimed ownership of 258,000 shares (SEC Form 3)

      3 - DarioHealth Corp. (0001533998) (Issuer)

      3/7/25 4:05:19 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Director Kaplan Jon H. was granted 30,000 shares, increasing direct ownership by 37% to 111,574 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      2/25/25 4:02:22 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Stern Adam K

      4 - DarioHealth Corp. (0001533998) (Issuer)

      1/10/25 4:04:16 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care